Novel immunoregulatory drugs to treat bacterial gastritis
Official title: Novel Immunoregulatory Therapeutics for Bacterial Gastritis
Funded at Biotherapeutics, INC. · NIH-11310525 · Data updated 2026-11-12
A new biotech project uses AI and lab work to create oral medicines that calm the stomach’s inflammation caused by Helicobacter pylori.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Biotherapeutics, INC. NIH-funded |
| Lab location | 1 site (Blacksburg, UNITED STATES) |
| Project start | August 13, 2026 |
| Project end | January 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $314,363 |
| NIH project number | 1R43AI197314-01 |
| Project ID | NIH-11310525 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with diagnosed bacterial gastritis or H. pylori-related gastritis who have or are at risk for chronic gastric inflammation.
✕Less likely to help
Patients without bacterial gastritis or those not able to participate due to medical risk factors may not benefit.
What this research studies
This project aims to speed up the development of oral therapies that reduce stomach inflammation from H. pylori using a blend of computational modeling and translational experiments. It focuses on precision immunology to identify treatments that can help patients with bacterial gastritis and potentially prevent related conditions. The team combines advanced AI approaches with lab studies to move promising candidates toward clinical testing quickly. If successful, patients could see new options beyond standard antibiotics, with a focus on durability and safety.
Why it matters
Potential benefit: If successful, patients with bacterial gastritis may gain new oral treatments that reduce inflammation and improve stomach health.
How similar studies have gone: There is ongoing research linking targeted immunomodulation to better control of gastric inflammation, with some approaches showing promise in early stages.
Where this research is happening
-
Biotherapeutics, INC.
Blacksburg, United States Active
Researchers
- Principal investigator: Hontecillas, Raquel — Biotherapeutics, INC.
- Study coordinator: Hontecillas, Raquel
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.